Laboratory Investigation
United States and Canadian Academy of Pathology The United States and Canadian Academy of Pathology
LWW Lippincott Williams and Wilkins
publishes Laboratory Investigation
--
                                      View Future Titles
Through Mar 2001
       Archives
Aug 1965 - Feb 2001
       Search Articles
Aug 1965 - Feb 2001
       Browse by Subject
Aug 1965 - Feb 2001
                      
Instructions to authors

Subscriptions

About the journal
   
  Direct Actions of Angiopoietin-1 on Human Endothelium: Evidence for Network Stabilization, Cell Survival, and Interaction with Other Angiogenic Growth Factors
Editorial board

Email alerts

'Net Tips

Help

Feedback

Guestbook








  Andreas Papapetropoulos, Guillermo García-Cardeña, Thomas J. Dengler, Peter C. Maisonpierre, George D. Yancopoulos, and William C. Sessa
   
  Departments of Pharmacology (AP, GG-C, WCS) and Pathology (TJD), The Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, Connecticut; and Regeneron Pharmaceuticals, Inc. (PCM, GDY), Tarrytown, New York
   
 

Angiopoietin-1 (Ang-1) is a recently described angiogenic protein that activates the endothelial Tie 2 receptor. Disruption of the Ang-1 gene shows that it has an indispensable role in blood vessel development, but it is not clear what specific effects, if any, Ang-1 has on endothelial cell (EC) phenotypes. Here, we show that Ang-1 dose-dependently stabilizes HUVEC network organization for up to 48 hours; this action of Ang-1 is dependent on Tie-2 receptor activation, because a soluble form of the Tie2-, but not the Tie1-receptor, completely blocks the effects of Ang-1. Moreover, we show that Ang-1 potentiates the actions of other angiogenic growth factors. Ang-1 markedly increases the survival of vascular networks (up to 96 hours) exposed to either vascular endothelial growth factor or endothelial cell growth supplement, a form of acidic fibroblast growth factor. In addition, Ang-1 prevents apoptotic death in HUVEC triggered by withdrawal of endothelial cell growth supplement. Collectively, these data are consistent with the idea that Ang-1 directly acts on human EC and interacts with other angiogenic molecules to stabilize vascular structures by promoting the survival of differentiated ECs.